What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Diagnostic value of dual-tracer PET/CT with [Frontiers in medicine · 2025
   Pooled it
2. Association between HIF1A rs11549465 polymorphism and risk of prostate cancer: a meta-analysis.Oncotarget · 2017
   Pooled it
3. Diagnostics (Basel, Switzerland) · 2023
   Article
4. The Added Value ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
   Article
5. Multimodal Imaging-Based Potential Visualization of the Tumor Microenvironment in Bone Metastasis.Cells · 2021
   Review
6. Diagnostic value ofEuropean journal of nuclear medicine and molecular imaging · 2021
   Article
7. Use ofFrontiers in oncology · 2021
   Article
8. Liquid Biopsy in Oligometastatic Prostate Cancer-A Biologist's Point of View.Frontiers in oncology · 2019
   Review
9. Trigger pSA predicting recurrence from positive choline PET/CT with prostate cancer after initial treatment.Oncotarget · 2018
   Article
10. TheOncotarget · 2017
    Article
11. Case: Incidental 18F-fluorodeoxyglucose-positron emission tomography/computed tomography prostate uptake: How should these patients be managed?Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2017
    Article
12. An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3'-deoxy-3'[(18)F]-Fluorothymidine Positron Emission TomographyDiagnostics (Basel, Switzerland) · 2017
    Article
13. Is There Use for FDG-PET in Prostate Cancer?Seminars in nuclear medicine · 2016
    Review
14. PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as